Home / Intelligence / Case Studies / Mapping Payer & Employer Perceptions of Novel Migraine Therapies to Support Access Strategy Development
Trinity conducted a payer and employer advisory board to understand current perceptions of novel migraine therapies and potential strategies to improve access.
Geographic Scope: 
Client Situation
The client wanted to gather the payer and employer perspective on how the migraine landscape is evolving, and pressure test key strategic options as well as messages that they had developed. The employers included: Coca-Cola Company, Metro Nashville Public Schools, St. Louis Community College, and Vibra Healthcare.
Trinity’s Solution
Trinity conducted an unblinded advisory board with a diverse set of payers and employee benefit managers to understand current perceptions of the migraine landscape and the employer interaction with payers as it pertains to influencing employee access to novel migraine therapies.
Deliverables
- Moderator Guide targeting each advisory board stakeholder
- Pre-Survey and Workbook materials designed to capture individual data responses
- Two advisory board sessions where the client played an active role – including individual payer and employer breakout sessions
- Final Report and Executive Summary synthesizing live / written payer and employer insights, highlighting strategic opportunities, challenges, and recommendations
Project Outcomes & Impact
Bringing together both payers and employers into an ad board setting created a real-world dynamic that is not often simulated through market research activities. The feedback within the section on “Cross-Stakeholder Approaches to Engagement on Migraine” provided the client with clear insights on how to effectively engage both stakeholder groups, with a primary output being a tool that payers can use to educate their employer clients on costs associated with migraine and to inform them on how to mitigate costs for their organizations.
Related Intelligence
Blog
Joint Clinical Assessment in the EU: What Life Sciences Companies Need to Know
March 2025 marked a pivotal moment for pharmaceutical and biotech companies operating in the European Union (EU) as the first two molecules began to proceed through the Joint Clinical Assessment (JCA) process. At a recent seminar hosted by Trinity Life Sciences, stakeholders gathered to explore the implications of this new regulatory framework and how to […]
Read More
Blog
Pricing and Access in Germany: Innovation and Strong Evidence Rewarded
Germany’s Medical Research Act (Medizinforschungsgesetz or MFG), which came into force on October 30, 2024, is a major legislative reform aimed at strengthening Germany’s position as an attractive environment for medical innovation and pharmaceutical development. The act provides for confidential negotiated drug pricing, incentives for local clinical trials, simplified clinical trial approvals and harmonization of […]
Read More
Blog
Seizing the Storm: Why Pharma Must Plan, Not Panic in Trump’s Second Term
The first 100 days of President Trump’s return to the White House have been anything but ordinary. With a true “Flood the Zone” strategy, there has been a flurry of executive orders, leadership reshuffles, and a re-assertion of executive power, which has signaled the administration is interested in seeing what policy options can “stick.” While […]
Read More